C12-2aN
Version 1.a56fc9f9 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | C12-2aN |
| Synonyms | Not available |
| SMILES | CCCCCCCCCCC(O)CN(CCCN1CCN(CCCNC(=N)CCCCC(=N)NCCCN2CCN(CCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC2)CC1)CC(O)CCCCCCCCCC |
| Formula | C₇₄H₁₅₂N₁₀O₄ |
| M.Wt | 1,246.0960 |
| Purity | 98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Kim D, Gong N, Alameh M-G, Han EL, Wang H, Wang J, Feng E, Yoon I-C, Murray AM, Shi Q, Moon S-J, Mrksich K, Weissman D, Mitchell MJ. Crosslinked ionizable lipids reprogram dendritic cell metabolism for potent mRNA vaccination. Nature Materials. 2026. |
C12-2aN is a crosslinked ionizable lipid developed for mRNA vaccine delivery and dendritic-cell metabolic reprogramming. Its structure combines two piperazine-based ionizable amine cores, a bis-amidine crosslinker, and four hydroxylated C12 hydrophobic tails. When formulated with DOPE, cholesterol, and C14-PEG2000, C12-2aN LNPs enhanced mRNA endosomal escape and activated AMPK–mTORC2-dependent glycolysis, supporting dendritic-cell maturation and antigen presentation. In preclinical mouse studies, C12-2aN LNPs generated robust humoral and cellular immune responses in SARS-CoV-2 RBD and OVA cancer-vaccine models. The formulation also demonstrated reduced liver-associated off-target expression and lower acute inflammatory markers than the tested control formulations. C12-2aN is a preclinical research lipid intended for evaluating metabolically active mRNA vaccine delivery systems.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →